Gene therapy has seen immense progress in recent years, and one company is leading the charge.
GENORASIS™ is leveraging groundbreaking advancements in research and development to produce innovative and unique therapies with the aim of transforming healthcare.
From utilizing cutting-edge technology and partnering with leading scientists to investing heavily in research and development, this company is pushing the boundaries of healthcare.
As a result of these efforts, GENORASIS™ would soon be able to introduce novel therapies that can be used to effectively treat a wide range of ocular diseases and health conditions of Central Nervous System.
GENORASIS™ has the ability to develop treatments that are more effective and efficient than traditional methods and drastically improve the quality of healthcare globally. In addition, our therapies could reduce the overall cost of healthcare and health insurance, making it more accessible to those who need it most.
Our Proof of Concept study is meticulously outlined and poised to usher in a new era of medical breakthroughs.
This study aims to unlock the potential of regenerating damaged axons of neurons, offering a ray of hope to individuals who have suffered vision loss due to glaucoma, neuritis, or optic nerve injuries.
Our optimism extends beyond ocular conditions – we believe this method holds promise for treating a range of peripheral nerve disorders, including spinal injuries.
As we stand on the threshold of this transformative endeavor, we extend an invitation to visionary investors who dare to dream alongside us.
By completing our investor's form, you can become an integral part of the journey toward groundbreaking solutions for vision restoration and the advancement of medical science.
Q: Mrs. Parrish, as a pioneer in the longevity community, how crucial is good vision in the context of achieving extreme longevity?
L.P.: Vision plays a crucial role in overall well-being and quality of life as we age. Maintaining good vision allows individuals to engage in daily activities, stay independent, and enjoy a higher quality of life. Poor vision, on the other hand, can lead to limitations, reduced mobility, and a greater risk of accidents and falls. By preserving and enhancing vision health, we contribute to a longer and more fulfilling life.
Q: What inspired you to address the challenge of glaucoma and vision loss?
L.P.: Sight is an invaluable gift that millions of people lose to glaucoma. In response to this pressing challenge, I set out to assemble an exceptional team to address this condition.
GENORASIS emerged as the clear answer, with groundbreaking gene therapy offering hope and potential for vision restoration.
Q: Doctor Papazoglou, what motivated you to undertake the challenging mission of seeking a cure for glaucoma through gene therapy?
N.P.: In my 25 years as a doctor, I've seen the devastating impact of glaucoma on thousands of people. It can slowly steal a person's vision without any noticeable symptoms until it's too late. I've seen the frustration and despair in my patients' eyes when they learn that the damage caused by glaucoma cannot be reversed. I am a strong supporter of the power of gene therapy and I believe it has the potential to revolutionize glaucoma treatment and offer a ray of hope to those affected by this condition.
We are thrilled to share the exciting news that our co-founder, Liz Parrish, will be a distinguished speaker at the upcoming Longevity Summit, scheduled to take place from August 17th to 20th, 2023, in Dublin. This premier event gathers thought leaders, experts, and innovators from across the globe to explore cutting-edge advancements and insights in the field of longevity and healthspan.
Mark your calendars for August 19th, as Liz takes the stage to share her profound insights on longevity and nerve regeneration. With a deep-rooted passion for promoting healthy living and a profound understanding of gene therapy, her talk promises to be a highlight of the summit.
© 2023 GENORASIS™ - All rights reserved